JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hoare, S. R. J.
Right arrow Articles by Usdin, T. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hoare, S. R. J.
Right arrow Articles by Usdin, T. B.

Vol. 289, Issue 3, 1323-1333, June 1999

Measurement of Agonist and Antagonist Ligand-Binding Parameters at the Human Parathyroid Hormone Type 1 Receptor: Evaluation of Receptor States and Modulation by Guanine Nucleotide1

Sam R. J. Hoare, Gerda de Vries2 and Ted B. Usdin

Unit on Cell Biology, Laboratory of Genetics, National Institute of Mental Health, (S.R.J.H., T.B.U.) and Mathematical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases (G.dV.), National Institutes of Health, Bethesda, Maryland

Determination of ligand-binding constants for parathyroid hormone (PTH) receptors has been hampered by a lack of suitable experimental systems and mechanistic models for data analysis. In this study, ligand binding to the cloned human PTH-1 receptor was measured using membrane-based radioligand-binding assays. Guanosine 5'-O-(3-thiotriphosphate) (GTPgamma S) (10 µM) reduced binding of agonist radioligands [125I]rPTH(1-34) and [125I]PTHrP(1-36) but only to a limited extent (by 29 ± 5 and 42 ± 3%, respectively). Radiolabeled agonist dissociation was described by three and two phases in the absence and presence of GTPgamma S, respectively. GTPgamma S treatment removed a pseudoirreversible binding phase. Inhibition of radiolabeled antagonist ([125I]bPTH(3-34)) binding was measured using a 90-min incubation, which allowed binding of ligands to closely approach the asymptotic maximum. Agonist/[125I]bPTH(3-34) displacement curves were fitted best by assuming two independent affinity states, both in the presence and absence of GTPgamma S. After a 3-h incubation, binding of PTH agonists in the presence of GTPgamma S was described by a single affinity state, indicating the presence of slow components in the binding reaction. Antagonist binding was described by a single affinity state and was not significantly affected by GTPgamma S. The data were used to evaluate potential receptor-binding models. Although other models could not be excluded, all of the observations could be explained by assuming two binding sites on the receptor that recognize two corresponding sites on agonist ligands. Using the model, it was possible to estimate receptor-ligand-binding constants and to propose a direct method for identifying ligands that interact with a putative antagonist binding region of the receptor.


0022-3565/99/2893-1323$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by U.S. Government






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.